DOSTINEX -
Medical Uses

    "…in giant, aggressive prolactinomas, cabergoline (Dostinex) represents a first-line therapy effective in reducing PRL levels and determining tumour shrinkage."

Corsello SM, Ubertini G, Altomare M, Lovicu RM, Migneco MG, Rota CA, Colosimo C.
Institute of Endocrinology, Catholic University School of Medicine, Rome, Italy. May 2003

    "These data indicate that cabergoline is a very effective agent for lowering the prolactin levels in hyperprolactinemic patients and that it appears to offer considerable advantage over Bromocriptine in terms of efficacy and tolerability"

Sabuncu T, Arikan E, Tasan E, Hatemi H.
Harran University, Medical Faculty, Department of Endocrinology and Metabolism, Sanliurfa, Turkey. Sep 2001

    "Given that these patients had advanced disease which makes it difficult to find significant therapeutic effects, medical therapy with potent dopamine agonists such as cabergoline (Dostinex) may evolve as a novel therapeutic option in a subgroup of patients with clinically nonfunctioning tumours declining operation and radiotherapy"

Lohmann T, Trantakis C, Biesold M, Prothmann S, Guenzel S, Schober R, Paschke R.
Department of Internal Medicine III, University of Leipzig, Germany. Tobias. August 2001

    "Cabergoline (Dostinex) was shown to be significantly more effective than Bromocriptine in inducing a complete biochemical response and clinical efficacy and was better tolerated than Bromocriptine in the majority of patients. Notable tumour shrinkage until tumour disappearance was observed during cabergoline treatment in most patients with macroprolactinoma and it was also proven effective in patients resistant to or with a poor response to Bromocriptine …
The great efficacy of this compound together with its excellent tolerability makes this drug the current treatment of choice for the majority of patients with hyperprolactinaemic disorders"

Colao A, di Sarno A, Pivonello R, di Somma C, Lombardi G.
Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, via S. Pansini 5, 80131 Naples, st1:country-region w:st="on">Italy. June 2002

    "These data indicate that cabergoline is a very effective agent for lowering the prolactin levels in hyperprolactinemic patients and that it appears to offer considerable advantage over Bromocriptine in terms of efficacy and tolerability"

Sabuncu T, Arikan E, Tasan E, Hatemi H.
Harran University, Medical Faculty, Department of Endocrinology and Metabolism, Sanliurfa, Turkey. Sep 2001

    "Dostinex has been approved for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas (tumors). Dostinex has been very successful in treating hyperprolactinemia and has been proved much more successful in doing so than Parlodel (Bromocriptine )"

Dostinex patient information

Top

    "Six months of treatment with cabergoline normalized testosterone levels in most cases, thus restoring and maintaining during treatment the capability of normal sexual activity in hyperprolactinemic males"

De Rosa M, Zarrilli S, Vitale G, Di Somma C, Orio F, Tauchmanova' L, Lombardi G, Colao A.
Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, 80131 Naples, Italy. Feb 2004

Top

    "Cabergoline (Dostinex) significantly improved early morning motor function, and in spite of increased phase shifts and awakenings, patients felt significantly more refreshed in the morning during cabergoline therapy"

Hogl B, Rothdach A, Wetter TC, Trenkwalder C.
Max Planck Institute of Psychiatry, Department of Neurology, Munich, Germany. Oct 2003

    We suggest that cabergoline (Dostinex) is an adequate adjuvant treatment for Parkinson' disease. There is improvement in motor symptoms (without substantially increased dyskinesias), reduced severity and duration of the wearing-off period, and diminished need for levodopa. Cabergoline can also be useful in the treatment of sleep disturbances associated with advanced Parkinson's disease such as nocturnal akinesia and dystonia.

Pastor P, Tolosa E.
Unidad de Parkinson y Movimientos Anormales Servicio de Neurologia, Institut Clinic de Malaties del Sistema Nervios, IDIBAPS, Hospital Clinic, Facultad de Medicina de la Universidad de Barcelona, Barcelona, Spain. May 2003

    "Treatment with cabergoline (Dostinex) showed higher efficacy and greater safety than other parkinsonian drugs"

Baas HK, Schueler P.
Department of Neurology, Central Hospital Hanau, Germany. 2001

    "The efficacy of cabergoline (Dostinex) in Parkinson's Desease patients with nocturnal disabilities, restless leg syndrome and augmentation has also been demonstrated. Audits of the clinical efficacy of cabergoline indicate that it is well-tolerated and has an acceptable side effect profile."

Marco AD, Appiah-Kubi LS, Chaudhuri KR.
Movement Disorders Unit, Mapother House, King's College Hospital, Denmark Hill, London, UK.
Oct 2002

    "Our data suggest that cabergoline has neuroprotective effects useful for Parkinson's disease therapy"

Lombardi G, Varsaldi F, Miglio G, Papini MG, Battaglia A, Canonico PL.
DISCAFF Department, University of Piemonte Orientale, Via Bovio 6, 28100 Novara, Italy. Dec 2002

 <Click here for full research and medical references>

Top

    "Cabergoline (Dostinex) alleviated RLS symptoms in 70-90% of patients"

Happe S, Trenkwalder C.
Department of Clinical Neurophysiology, University of Gottingen, Gottingen, Germany2004

    "Low doses of cabergoline (Dostinex) showed effectiveness and safety in patients with moderate to severe RLS, with no appearance of augmentation phenomenon"

Zucconi M, Oldani A, Castronovo C, Ferini-Strambi L.
Sleep Disorders Center, Department of Neurology, H San Raffaele Scientific Institute and Hospital, Universita Vita-Salute San Raffaele, Milan, Italy.
Nov 2003

    "An open pilot study shows that the long-acting dopamine agonist cabergoline is a promising new tool in the treatment of RLS"

Stiasny K.
Department of Neurology, Center of Nervous Diseases, Marburg, Germany. 2001

<Click here for full research and medical references>

Top

    "A single dose of cabergoline (Dostinex) during hospitalization improves the patients' compliance and thus the effect of treatment. Cabergoline (Dostinex)can be used as the drug of first choice for arrest of lactation after abortion during the second trimester of pregnancy."

Pavlista D, Calda P, Zivny J.
Gynekologicko-porodnicka klinika 1. LF UK a VFN v Praze. Jan 2003

    "Our conclusion is that Dostinex is the most effective agent for prevention of the postpartal lactation given once a day (2 table.) in the first 24 h. post delivery. We read good effect when the medicine was taken twice daily x 1/2 table. for 2 days. Dostinex shows vary good compliance and low rate of relapse of the Lactation"

Bozhinova S, Porozhanova V, Penkov V. 2001

<Click here for full research and medical references>

Top